← 返回

源自 NK 细胞相关基因的前列腺癌诊断特征:整合 scRNA-seq 与 bulk RNA-seq 分析的见解及 KIT 的功能验证

英文原题:A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT.

查看英文原题

A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT.

PubMed 2026/06/03(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究为前列腺癌诊断中 NK 细胞相关基因特征提供了新的认识,并强调 KIT 作为未来治疗研究的有前景候选靶点。需要进一步研究以探索这些基因表达的机制及其在肿瘤微环境中的作用。

研究思路结论见上方概要

前列腺癌是男性泌尿生殖系统最常见的恶性肿瘤之一。在前列腺癌中观察到的自然杀伤(NK)细胞活性受损可能有助于免疫逃逸。本研究旨在开发稳健的NK细胞相关诊断特征。

基于scRNA-seq分析鉴定的NK相关基因,采用加权基因共表达网络分析、最小绝对收缩和选择算子回归分析以及机器学习算法,构建了一个新的诊断模型。利用从前列腺癌患者采集的肿瘤组织和癌旁正常组织验证了诊断基因的表达。进一步在前列腺癌细胞中评估了KIT作为NK细胞相关基因的生物学功能。

一个包含九个基因的NK细胞相关诊断特征被开发出来,包括HSPD1、HSPE1、CLU、KIT、LAPTM4A、SLC18A2、TUBA4A、VWA5A和ZFP36L1。这些基因在独立数据集中得到验证,并显示出对前列腺癌诊断的强大预测能力(AUC >0.8)。基于这些基因的表达谱,鉴定出九种可能影响前列腺癌药物敏感性的化合物。此外,CLU、TUBA4A和KIT的表达在收集的前列腺癌组织样本中成功得到验证。功能实验表明,KIT过表达增强了NK-92细胞对前列腺癌PC-3细胞的细胞毒性,抑制了癌细胞的活力、细胞迁移和侵袭,并增加了IFN-γ、Gzms-A、Gzms-B和Perforin等细胞因子的分泌,以及脱颗粒标志物CD107a。

展开英文摘要原文

Prostate cancer is one of the most common malignant tumors of the male genitourinary system. The impaired activity of natural killer (NK) cells observed in prostate cancer may contribute to immune evasion. This study aimed to develop robust NK cell-related diagnostic signatures.

Based on NK related genes identified by scRNA-seq analysis, weighted gene co-expression network analysis, least absolute shrinkage and selection operator regression analysis, and machine learning algorithms were used to develop a novel diagnostic model. The expression of diagnostic genes was validated using tumor and adjacent normal tissues collected from prostate cancer patients. The biological functions of KIT as an NK cell related gene were further evaluated in prostate cancer cells.

A nine-gene NK cell-related diagnostic signature was developed, including HSPD1 , HSPE1 , CLU , KIT , LAPTM4A , SLC18A2 , TUBA4A , VWA5A , and ZFP36L1 . These genes were validated in independent datasets and showed strong predictive ability for prostate cancer diagnosis (AUC >0.8). Based on the expression profiles of these genes, nine compounds were identified that may influence drug sensitivity in prostate cancer. Furthermore, the expressions of CLU , TUBA4A , and KIT were successfully validated in collected prostate cancer tissue samples. Functional experiments demonstrated that KIT overexpression enhanced the cytotoxicity of NK-92 cells against prostate cancer PC-3 cells, inhibited cancer cell viability, cell migration and invasion, and increased the secretion of cytokines such as IFN-γ, Gzms-A, Gzms-B, and Perforin, as well as the degranulation marker CD107a.

This study provides a new understanding of NK cell related gene signatures in prostate cancer diagnosis and highlights KIT as a promising candidate for future therapeutic investigation. Further research is needed to explore the mechanisms underlying the expression of these genes and their roles in the tumor microenvironment.

论文信息

作者
Chen Z、Zhou F、Tian J、Lv Q、Wang D、Fan S
单位
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.China
期刊
Frontiers in immunology2026
原文标识
PubMed 42317356 · DOI 10.3389/fimmu.2026.1692792